Immunocore Holdings PLC (IMCR) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and …

GuruFocus News

Thu, February 26, 2026 at 4:01 AM GMT+9 4 min read

In this article:

IMCR

-2.32%

This article first appeared on GuruFocus.

**Net Revenue:** $400 million from KimTrack, up 29% from the prior year.

**Cash and Marketable Securities:** Approximately $864 million, an increase of over $40 million from the previous year.

**KimTrack Approval and Launch:** Approved in 39 countries and launched in 30 markets.

**Market Penetration:** Over 70% penetration across all major markets for KimTrack.

**Mean Duration of Therapy:** 14 months for KimTrack.

**Operating Expenses:** Increased due to investments in three phase 3 trials and early-stage programs.

**SG&A Expenses:** Marginally higher than 2024, with expected incremental increases in 2026.

**Operating Loss:** Reduced in 2025 as revenue growth outpaced operating expenses.

Warning! GuruFocus has detected 4 Warning Signs with IMCR.

Is IMCR fairly valued? Test your thesis with our free DCF calculator.

Release Date: February 25, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Immunocore Holdings PLC (NASDAQ:IMCR) reported a 29% increase in net revenue for 2025, reaching $400 million, driven by the success of KimTrack.

KimTrack is now approved in 39 countries and launched in 30 markets, with significant penetration in the US and Europe.

The company has a strong balance sheet with $864 million in cash, providing flexibility to advance its pipeline.

Immunocore is expanding its oncology platform beyond melanoma into ovarian, lung, colorectal, and GI cancers.

The company is advancing its pipeline with three ongoing phase 3 trials in oncology and promising developments in infectious disease and autoimmune programs.

Negative Points

Growth for KimTrack is expected to moderate as it enters its fifth year on the market, with significant penetration already achieved.

Operating expenses increased due to ongoing investments in phase 3 trials and early-stage programs, impacting profitability.

The competitive landscape in melanoma and other cancer types could impact future market share and pricing strategies.

The company faces challenges in expanding its pipeline into new therapeutic areas, which may require significant investment and resources.

There is uncertainty regarding the timing of data readouts and potential regulatory approvals, which could affect future growth projections.

Q & A Highlights

Q: Can you provide details on the geographic breakdown of enrollment for the TEBY A am trial and any DSMB analysis conducted? A: The majority of enrollment for TEBY A am is from Europe, with 10-15% from the US. The trial design was converted into a phase 3 seamless trial based on enrollment metrics, saving a year in trial conduct. No DSMB analysis was conducted on mono versus combo activity.

Story Continues  

Q: What are the statistical assumptions for the TEBY A am trial, and what is the likelihood of success for the monotherapy arm? A: The study is designed to meet statistically significant and clinically meaningful thresholds, typically at least a 30% difference from the control. While the combo may outperform the mono, specific statistical details are not disclosed.

Q: How do you view the commercial outlook for Kimtrak, especially with potential deceleration in sales growth? A: We expect growth to moderate as Kimtrak enters its 5th year on the market with significant penetration. Year-on-year growth was 29%, but normalizing for rebate reserves, underlying growth was around 20%. We aim to maintain cash flow break-even while investing in phase 3 trials.

Q: How do you plan to approach pricing for Kimtrak in the second line cutaneous melanoma market? A: Given the unmet need in advanced melanoma and the potential overall survival benefit, we believe we can defend the current pricing, contingent on positive data outcomes.

Q: What are the expectations for the HIV program’s upcoming data update, and how high can the dose be pushed? A: The HIV trial is in the multiple ascending dose phase, with small cohort sizes. By year-end, we aim to identify the right dose and assess its impact on the viral reservoir and rebound. Expansion can be triggered based on data signals.

Q: How do you evaluate success in early autoimmune studies relative to oncology benchmarks? A: We chose type 1 diabetes to determine early on if the drug binds the target and measure efficacy using surrogate markers like C peptide. This approach helps assess potential activity before larger phase 2B trials.

Q: How do you view the evolving landscape for ChemTrack in second line cutaneous melanoma, considering potential competition? A: Currently, the only approved therapy is TILs, which is highly selective. ChemTrack’s OS endpoint and off-the-shelf availability, along with established safety and experience, provide a competitive advantage.

Q: What are the expectations for the upcoming ovarian and lung readouts for Brenny, and what will guide further development? A: We have seen activity in ovarian cancer and are focusing on safety and early signals in maintenance settings. Lung cancer data will include heterogeneous subsets. The totality of data, including safety and efficacy, will guide next steps.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Terms and Privacy Policy

Privacy Dashboard

More Info